A Study of Tolerability and Efficacy of Cannabidiol on Motor Symptoms in Parkinson's Disease
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
The major purpose of this study is to assess the efficacy of CBD on motor symptoms of
Parkinson's Disease (PD), and secondarily to study the safety and tolerability of CBD and
other efficacy, particularly regarding tremor in PD. The study has been powered to detect a
clinically significant reduction in Movement Disorder Society (MDS) Unified Parkinson's
Disease Rating Scale (UPDRS) Part III motor scores. This is a 1:1 parallel, double-blind,
randomized controlled trial (RCT) with 60 participants. The investigators will be recruiting
up to 75 participants; the goal is to have 60 participants (30 in CBD group and 30 in placebo
group) complete the study. The study drug is obtained from the National Institute on Drug
Abuse (NIDA).
Phase:
Phase 2
Details
Lead Sponsor:
University of Colorado, Denver
Collaborator:
Colorado Department of Public Health and Environment